Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.6259+0.0624 (+11.07%)
At close: 04:00PM EDT
0.5978 -0.03 (-4.50%)
After hours: 07:40PM EDT
Advertisement
Sign in to post a message.
  • S
    Soren
    Reasons to be optimistic:

    This year was driven up from 2.70 to nearly 10 bucks in the months following the arthritus drug fail and has been in free fall ever since over the last 18 months.

    It has fallen on good news not bad - the company was at its worst position at a price higher than in the weeks before the collapse. The movement from up to 10 bucks post ubx0101 fail was clearly artificial - and it held for months.

    If that can be sustained then so can its opposite. The SP has clearly been manipulated day in day out for some time - yesterday another example. It was up 5 % had an hour before the close, as much as 8% earlier, yet was brought down in the last few minutes to absolute level. It has been consistent.

    Bringing the share price down to set the following day's opening price seems to be important - the share price isn't allowed to climb. But it clearly was, dramatically so, when the stock was overvalued.

    The science still looks strong, senolytics do work and this trial looks very promising. On good phase results the stock has fallen 75% (2.40 just prior to release) mirroring the inverse two years ago when it fell immediately to 2.70 in the days after the failed drug results but climbed to 9.80ish. In fact post P1 I believe it spiked to 3.60, though it doesnt show on the yahoo charts.

    The company had a big fail, but is recovering.

    Hopefully, the company, is securing funding as we speak, on the back of positve p2 results. Let's hope its not dilution at these prices.

    https://www.fightaging.org/archives/2020/08/unity-biotechnology-fails-phase-ii-trial-of-localized-senolytics-for-knee-osteoarthritis/

    One of the comments remarks that the phase ones weren't that great unlike the recent eye trials. The complaint too was of poor experimental design - targetting inflammation through local injection.

    The criticism wasn't aftertiming either, as mentioned earlier:

    https://www.fightaging.org/archives/2019/05/unity-biotechnologys-locally-administered-senolytic-trials/

    I personally have found benefits through taking fisetin, a natural senolytic, on an arthritic knee. There is significant improvement in dosed subjects in these phase one trials so reason to be optimistic.

    The movements of
    UNITY Biotechnology is the largest of the handful of biotech startups working on senolytics, therapies capable of selectively destroying a sizable fraction of the senescent cells that accumulate in old tissues. The company entered clinical trials wit
    UNITY Biotechnology is the largest of the handful of biotech startups working on senolytics, therapies capable of selectively destroying a sizable fraction of the senescent cells that accumulate in old tissues. The company entered clinical trials wit
    www.fightaging.org
  • N
    Nicholas
    I knew someday this would be worthless yet I held on.
  • N
    Nicholas
    One day this stock will go up 2000% so I can break even.. BLAHAHAHA
  • B
    Bruce
    This stock is the scam of the century.
  • J
    James
    Yes, I bought into the hype (BS?) of the magic pill that would change the world! Not in for very much so even if it goes to $0 the loss is minimal. But! this is also a fledgling start-up firm with a "who knows?" future. So, with that said, I think it is worth an additional small investment to cost-average down. I added 900 shares at today's low price, and we'll just see where this goes. GLTA.
  • T
    Tim
    Reverse split might be ok.
    Bullish
  • p
    paul
    Wasn't this the company that awhile back supposedly had the pill that could spell the end of aging? What happened to that?
  • s
    shekhar
    In UBX meeting trying to reverse split means this is dead investment get out and cut the loss
  • C
    CID1000
    Will UBX get delisted if price remains under $1/share?
  • B
    Bruce
    Ever get the feeling that this company was a scam?
  • M
    MS
    Great news! UBX1325 to advance to Phase 1 clinical development and with the first patient later on in this 2020 year. Wait for the news to be widely circulated during the two investors' conference presentations today and tomorrow. This will bounce to $4 quickly.
  • F
    Fuffu19
    hi guys, is it good time to join or is too high for the last month??? Iam researching for new opportunities and I would appreciated any input.
  • S
    Soren
    Commiserations to investors. Surprised with the result as I have a lot of faith in senolytics - I hope they undergo follow up tests one year later, some of the benefits may take time - pain is the most marketable metric however there may perhaps been improved resistance strength for example.

    But I have to say trust in this company has deteriorated, they need to root out the mole.

    Last week 17 x average volume was traded and the share price surged on no news (30-40% at one point?). Obviously there was some kind of leak or intent to trigger the perception of one. The short percentage was 42%, 3 million shares were borrowed to sell to investors riding the wave. The shorts were waiting for them, this wasn't a leak - it was a sting.

    And of course the impression was added to in the days running up with the price rising that results really were good after all why the price-hike?

    The SEC are a joke occasionally there will be some public hanging to reassure investors the sheriff has power, but how does this not flag? There has been plenty of quite obvious insider dealing during this crisis in a handful of stocks I've loosely monitored - easily tracked by data. Yet as far as I know only KODAK have been called out.

    Again commiserations - I would be interested to know views on what inferences can be drawn from the other senolytics.

    Thanks
  • p
    p-me
    3 day washout rule likely working with this one. As soon as traders see a bottom and a slight increase they will enter in drowes and push the price up by 10-20% imo. Good luck.
  • m
    michael
    new to the stock market and was wondering when would be a good time to sell this stock. I bought it at $3.16. I know nothing about the stock market or this company it was a lucky buy a guy at dinner told me. so if someone who has more insight than me could tell me when to sell that would be great. thanks
  • T
    Terry
    I have been long here awhile now though I rarely post. Earlier in the week a friend who I recommended UBX text me and ask should I sell. I said how much is it now and he replied over 15.00. I simply said I'm holding.
    UBX reminds me of DXCM. I bought it years ago in the 10's and sold 3 points later. Now look at it. Why am I comparing it you might ask. I think this has the potential to become another Dexcom. Will it, most likely not, though again this has much potential...
    Good luck longs
  • J
    J
    “Developing novel treatments that selectively eliminate or modulate senescent cells is at the heart of what we do, and we have generated valuable data that will enable us to learn from this study and inform future studies in diseases of aging," Unity CEO Anirvan Ghosh said in a statement.

    Unity, which said it has sufficient cash, equivalents and investments to fund operations "well into" 2022, will continue with studies of another drug, UBX-1325, for retinal diseases, including diabetic macular edema and diabetic retinopathy.

    Unity's osteoarthritis results came from the 12-week point of the study, but Unity said it will complete collection of data through 24 weeks as well as a higher-dose, repeat-dose Phase Ib study in the second half of this year.

    https://www.google.com/amp/s/www.bizjournals.com/sanfrancisco/news/2020/08/17/unity-biotechnology-ubx-osteoarthritis-knee-failed.amp.html
  • z
    z
    The CEO gave a presentation at Goldman Sachs yesterday. There were interesting updates on the drugs target eye and lung, especially lung (pulmonary fibrosis). It seems that the tone on UBX0101 was quite positive as the company is cleaning up the data for release (phase I).
  • s
    scott
    Some institutional investing action!  UBX stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Dimensional Fund Advisors LP, Ballentine Partners LLC, Cubist Systematic Strategies LLC, Nuveen Asset Management LLC, JPMorgan Chase & Co., Barclays PLC, and Alliancebernstein L.P..
Advertisement
Advertisement